UBS Group
LENZ

UBS Group’s LENZ Therapeutics LENZ Stock Holding History

UBS Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$635K Sell
111,825
-45,164
-29% -$364K ﹤0.01% 6086
2026
Q1 		$1.44M Sell
156,989
-1,414,749
-90% -$19.9M ﹤0.01% 5257
2025
Q4 		$25.1M Buy
1,571,738
+370,122
+31% +$10.8M ﹤0.01% 2360
2025
Q3 		$56M Buy
1,201,616
+320,135
+36% +$11.8M 0.01% 1516
2025
Q2 		$25.8M Buy
881,481
+214,317
+32% +$5.83M ﹤0.01% 2112
2025
Q1 		$17.2M Buy
667,164
+581,236
+676% +$14.3M ﹤0.01% 2503
2024
Q4 		$2.48M Buy
85,928
+79,783
+1,298% +$2.43M ﹤0.01% 4526
2024
Q3 		$146K Buy
6,145
+2,083
+51% +$46.2K ﹤0.01% 6091
2024
Q2 		$70.2K Sell
4,062
-209
-5% -$3.65K ﹤0.01% 6427
2024
Q1 		$95.4K Sell
4,271
-116
-3% -$2.41K ﹤0.01% 6245
2023
Q4 		$80.5K Buy
4,387
+2,151
+96% +$35.5K ﹤0.01% 6298
2023
Q3 		$38.8K Sell
2,236
-614
-22% -$10.7K ﹤0.01% 6454
2023
Q2 		$51.9K Buy
2,850
+1,569
+122% +$31.3K ﹤0.01% 6456
2023
Q1 		$22K Buy
1,281
+1,063
+488% +$17.2K ﹤0.01% 7016
2022
Q4 		$5.07K Hold
218
– – ﹤0.01% 9227
2022
Q3 		$5K Sell
218
-6,671
-97% -$159K ﹤0.01% 9243
2022
Q2 		$132K Buy
6,889
+6,133
+811% +$137K ﹤0.01% 5219
2022
Q1 		$27K Sell
756
-370
-33% -$23.1K ﹤0.01% 7113
2021
Q4 		$98K Buy
1,126
+768
+215% +$63.6K ﹤0.01% 6334
2021
Q3 		$41K Buy
+358
New +$53K ﹤0.01% 6508

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

UBS Group's LENZ Position: Q2 2026 in Review

UBS Group reduced its LENZ Therapeutics (LENZ) stake by 29% in Q2 2026, selling an estimated $364K and leaving 111,825 shares worth $635K. The position accounts for ﹤0.01% of the portfolio, ranked #6086.

UBS Group first reported a position in LENZ in Q3 2021 and has held it in 20 quarters since. The position peaked at $56M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • UBS Group held 111,825 shares of LENZ Therapeutics worth $635K as of Q2 2026.
  • UBS Group sold 45,164 LENZ Therapeutics shares in Q2 2026, an estimated $364K.
  • LENZ Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6086 holding.
  • UBS Group first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • UBS Group's LENZ Therapeutics position peaked at $56M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.